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ABSTRACT
Aim: Infectious diseases in infants are a major public health issue. Synbiotic-enriched
formulas (EF) are intended to mimic the beneﬁcial effects of human milk on infectious dis-
eases. We performed an observational study in infants switching to follow-on formula to
determine the effects of synbiotic-enriched formula compared to standard formula (SF).
Methods: We recorded family characteristics, medical history and growth data, as
well as the symptoms, severity and treatment of infectious diseases. Main outcome mea-
sures were compared after adjustments for baseline characteristics.
Results: Between January and June 2007, 771 healthy infants were included in the
study; 35.4% experienced at least one infectious disease during the 3-month study period.
The most common were upper respiratory tract (24.1%), otitis (6.6%) and gastrointestinal
infectious diseases (5.0%). Infants fed synbiotic-enriched formula had fewer infectious
diseases overall (EF: 31.0%; SF: 40.6%; p = 0.005) and signiﬁcantly fewer gastrointestinal
infectious diseases (EF: 3.5%; SF: 6.8%; p = 0.03). During follow-up, weight gain was
signiﬁcantly higher (p = 0.0467) in infants fed synbiotic-enriched formula
(18.3 ± 8.7 g⁄day) versus SF (16.9 ± 7.5 g⁄day).
Conclusions: Supplementation with synbiotics may have beneﬁcial effects on the incidence of
infectious disease and growth in infants. Further studies are needed determine optimal doses and
composition of synbiotics in infant formula.
INTRODUCTION
In the United States, more than 40% of all infant hospita-
lizations are attributable to infectious disease, resulting
in total annual hospital costs of approximately $690 million
in 2003 (1). Diarrhoeal diseases and digestive tract infec-
tions are the most common infectious diseases in infants.
Rotavirus gastroenteritis, for example, is known to affect
nearly every child by age 5 (2). Infectious diseases are very
frequent and are associated with substantial costs. Preven-
tive strategies could include functional nutrition of infants.
Special attention should be paid to infectious disease inci-
dence in infants switching from exclusive breast feeding to
follow-on formula. Breast feeding has been shown to have a
number of beneﬁcial effects in infants, including protection
against infectious and allergic diseases. Those effects are
probably mediated in part through modulation of intestinal
microﬂora (3,4). Oligosaccharides are likely to be involved
in this beneﬁcial modulation of microﬂora in breast-fed
infants (5), because they inﬂuence gastrointestinal develop-
ment and reduce respiratory and gastrointestinal illness in
infants (6).
To mimic these beneﬁcial effects of human milk on gut
microﬂora, prebiotic- and probiotic-enriched formulas have
been developed in the past 10 years. It has been suggested
that these formulas could reduce the incidence of infectious
diseases and atopy (7–9). Recently, new formulas have been
proposed that contain synbiotics, i.e. combined prebiotics
and probiotics (10,11). Synbiotics are expected to be more
beneﬁcial than probiotics or prebiotics alone, owing to
synergistic effects.
In this study, we investigated the incidence and types of
infectious diseases in healthy infants during the ﬁrst three
months of consumption of a new symbiotic-enriched
follow-on formula (EF) compared to infants consuming
standard formula (SF).
Abbreviations
EF, synbiotic-enriched formula; ITT, intention-to-treat; PP, per-
protocol; SF, standard formula.
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Study design
A prospective, multicentre, open study with two interven-
tion groups was carried out in France, with the collabora-
tion of family paediatricians. Three-hundred paediatricians
were randomly selected from the 1200 paediatricians prac-
ticing in France and were invited by letter to participate in
the study; 166 accepted. Infants aged between 4 and
6 months of age who needed follow-on formula were
enroled by 166 paediatricians scattered all over the French
territory, after informed written consent was obtained from
parents. Inclusion criteria were birth weight between 2 and
4.5 kg and no history of neonatal or digestive disorders.
Infants who had an immune deﬁciency were excluded.
Because of the pilot nature of the study and in line with
the proposal by participating family paediatricians, an
open study design was applied. This study was registered
with the French Medical Council to the National Consul-
tative Committee on Data Processing in Biomedical
Research.
Study protocol
During the inclusion visit, paediatricians alternatively pre-
scribed use of either one of the standard follow-on formula
(SF) or a synbiotic-enriched formula (EF) for 3 months. As
recommended in routine practice, follow-on formula was
proposed by paediatricians at the time of diversiﬁcation,
i.e. at beginning of diversiﬁcation or just before diversi-
ﬁcation. Both SF and EF formulas were commercially
available in France. SF was let to the choice of the paedia-
trician who chooses one of the commercially available
follow-on formulas without probiotics and prebiotics. The
nutrient composition of SF corresponded to values deter-
mined by European rules (energy: 70–74 kcal⁄dL, protein:
1.8–1.9 g⁄dL). The only EF available in France at the time
of the study was Nutriben 2 Prebiotiques and Probiotiques
(Nutriben, Les Ulis, France). Its composition corresponded
also to values determined by European rules (energy:
74 kcal⁄dL, protein: 1.9 g⁄dL). This formula contains fruc-
tooligosaccharides (28 mg⁄g of powder) and two probiotic
strains (Biﬁdobacterium longum at 10
7 UFC⁄g of powder
and Streptococcus thermophilus at 10
6 UFC⁄g of powder).
Neither EF nor SF contained nucleotides or other immuno-
logical factors.
Study end points and data collection
Primary outcome was the incidence of infectious diseases.
All episodes of infections were recorded during a follow-up
of3 months.Thediagnosiswasmadebythefamilypaediatri-
cian based on speciﬁc symptoms, and they were given
instructions on how to collect information about infectious
diseases on the basis of standardized deﬁnitions. Acute
diarrhoea was deﬁned as a stool pattern with 3 or more loose
or watery stools per day lasting for at least 3 days. Pharyngi-
tis,laryngitisandtracheitiswereconsideredasupperrespira-
torytractinfections.Antibioticcourseswerealsorecorded.
At inclusion, paediatricians collected data about the
infant’s birth, family history, parents’ smoking behaviour,
frequency of infections in parents, day care situation (day
care centre or home care), medical history (allergies and
number of infectious diseases since birth, treatments and
vaccines), feeding practices since birth and clinical exami-
nation data. At each monthly follow-up visit, they collected
anthropometric data, information about the occurrence of
infectious diseases since the last visit and at follow-up visits,
treatments and vaccination at follow-up visit and changes
in feeding since last visit (such as type of formula, amount of
formula, etc.). Secondary outcomes measured were weight
and length gain.
The survey protocol and questionnaires were presented
in person to all participating physicians. Telephone and
email helplines were set up at the beginning of the study
and maintained throughout for paediatricians and parents
who sought assistance or advice on any topic related to the
study. Quality audits were performed on six randomly
selected investigators by clinical research assistants to verify
that physicians were compliant with the protocol.
A questionnaire was developed for parents to record sus-
pected infectious diseases during the 3-month study period.
Prior to the start of the study, parents were given instruc-
tions on how to use the questionnaire and how to contact
the dedicated study hotline if necessary. Every time an
infectious disease was suspected, parents completed items
regarding the symptoms. If relevant, they also recorded
additional information about day care centre absences, hos-
pitalization, diagnosis and treatment.
Paediatricians read the parent questionnaire and ques-
tioned parents at each visit about infectious diseases noted
by parents. The ﬁnal visit was scheduled to take place
3 months after inclusion. Before statistical analysis, data
collected from the parent questionnaire and data collected
by the paediatrician were compared for each infant. Infec-
tious diseases were categorized as ‘possible’ or ‘conﬁrmed.’
Only infectious diseases reported to be ‘conﬁrmed’ by
paediatricians were included in the analysis.
Statistical analysis
Infectious disease incidence during the 3 months of formula
consumption was the primary outcome measure. Incidence
was expressed as the proportion of babies with one or more
episodes of certain infectious diseases. Based on data
published previously (12), we hypothesized that using milk
formula supplemented with synbiotics would reduce the
incidence from 40% to 30%. We calculated that for a power
of 80% (b = 0.20) and at a signiﬁcance level of .05
(a = 0.05), we needed 376 infants in each feeding group to
detect a 10% difference between the EF and SF groups.
To allow for an expected 10% dropout rate, we decided to
recruit 836 infants (418 infants in each group).
Continuous variables were expressed as mean ± standard
deviation. Exploratory intergroup comparisons were per-
formed according to the type of follow-on formula con-
sumed (SF or EF). All tests were two-sided. The risk of type
1 error (a) was set at .05 for the entire study. Means were
compared using Student’s t-tests. Categorical variables were
compared using v
2 or Fisher’s exact tests as appropriate. For
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baseline characteristics were performed using logistic
regression models (infectious disease incidence) or covari-
ance analysis (mean number of infectious diseases during
follow-up). There was no approximation of missing data;
instead, missing data items were omitted from the statistical
tests and not taken into account when calculating percent-
ages. The following were considered to be deviations from
the protocol: change of follow-on formula during study per-
iod (so that no follow-on formula was consumed at least
75% of the follow-up time) and no data for the main out-
come measure (infectious disease incidence). Intention-
to-treat (ITT) as well as per-protocol (PP) analyses were
performed.
To identify potential prognostic factors for infectious
disease in 4- to 6-month-old infants, a stepwise logistic
regression multivariate analysis was performed in the ITT
population in an exploratory way with the ‘Occurrence of
infectious disease (Yes⁄No)’ as the dependent factor. Vari-
ables considered for the multivariate modelling were vari-
ables with p < 0.20 in univariate logistic regressions (data
not shown). The entry and removal criteria for stepwise
selection were set to 0.10 and 0.15, respectively. The devi-
ance and Pearson goodness-of-ﬁt statistics as well as the
Hosmer–Lemeshow goodness-of-ﬁt were calculated. All
variables included in the model were tested for collinear-
ity. The 95% conﬁdence interval (95%CI) for the odds
ratio (OR) was calculated. Data analysis was performed
using the SAS statistical program, version 8.2 (SAS
Institute, Inc., Cary, NC, USA).
RESULTS
Participants
Between January 2007 and June 2007, 824 infants were eli-
gible to participate in the study (Fig. S1). Fifty-three infants
were not included because parents refused to provide
permission. Of the baseline sample, 94% (771 infants) were
included in the study: 422 consumed synbiotic-enriched for-
mula (EF group) and 349 consumed standard formula (SF
group). Most infants (58%) were included before the 1st of
April, and there was no signiﬁcant difference between feed-
ing groups (EF: 60.6%, SF 54.9%, p = 0.109). Baseline char-
acteristics are presented in Table 1. At birth, there was no
difference between feeding groups for body weight (EF:
3310 ± 410 g vs SF: 3270 ± 510 g, p = 0.559) and for
length (EF: 49.6 ± 2.0 g vs SF: 49.7 ± 2.1 g, p = 0.647).
Half (50.2%) of the subjects were male patients. The charac-
teristics of the 53 non-included subjects were similar to
those of included subjects (data not shown). Of the 771 sub-
jects, 27 subjects in the EF group and 52 subjects in the SF
group presented with at least one major protocol deviation
and were excluded from the PP population. Characteristics
of these excluded subjects were similar (data not shown).
PP analysis was thus performed on 692 infants (84% of the
baseline sample) (Figure S1). PP results are not shown but
were in line with results for the ITT population (presented
later).
Feeding practices and duration of follow-up
Before changing for a follow-on formula (inclusion), infants
were exclusively breast-fed (22%), exclusively formula fed
(54%) or received human milk together with formula (24%).
The proportion of subjects partly or exclusively breast-fed at
inclusion was similar in both groups (Table 1). The mean
daily volume intake was 750 ± 178 mL⁄day at the day
before inclusion; this decreased to 629 ± 183 mL⁄day at
the end of study period. It was similar between groups both
at inclusion (p = 0.68) and at the ﬁnal visit (p = 0.87).
Infant cereals were consumed by 28.1% of the cohort, and
similar proportions of infants consumed cereals in both
groups (p = 0.86). The mean follow-up duration was
2.8 ± 1.0 months and was identical between groups
(p = 0.65).
Table 1 Baseline characteristics in the intention-to-treat group (Mean ± standard deviation)
EF group SF group All infants
n 422 349 771
Age at enrolment (day) 153 ± 44 151 ± 34 152 ± 40
Weight at enrolment (kg) 6.96 ± 1.02 6.98 ± 0.90 6.97 ± 0.96
Length at enrolment (cm) 64.0 ± 3.7 64.2 ± 3.8 64.1 ± 3.81
Family history of allergy (%) 38.4
* 27.0 33.2
Personal history of allergy (%) 16.1
* 10.0 13.3
Number of siblings (n) 0.69 ± 0.84 0.60 ± 0.85 0.66 ± 0.84
Frequent infectious episodes in parents (%) 7.7 5.2 6.5
Smoking in the family home (%) 15.4 17.9 16.5
Number of infectious diseases since birth (n) 1.0 ± 1.3
* 0.7 ± 1.2 0.9 ± 1.2
Partly or exclusively breast feeding at inclusion (%) 47.2 45.5 46.4
Consumption of prebiotic- or probiotic-enriched
infant formula before inclusion (%)
20.6 15.4 18.3
Dietary diversiﬁcation before inclusion (%) 85.0 87.4 86.1
Daily volume of follow-on formula prescribed (mL) 748 ± 180 752 ± 176 750 ± 178
Addition of wheat to follow-on formula (%) 27.8 28.4 28.1
*p < 0.05 versus SF (Student’s t-test or v
2⁄Fisher’s exact test).
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During the study period, weight gain was signiﬁcantly
higher in infants fed EF (18.3 ± 8.7 g⁄day) than in those fed
SF (16.9 ± 7.5 g⁄day) (p = 0.047). The increase in length
tended to be also greater in the EF group (0.47 ±
0.22 cm⁄week) than in the SF group (0.45 ± 0.25 cm⁄
week), but the difference was not statistically signiﬁcant
(p = 0.069).
Incidence of infectious diseases
In the ITT analysis, 35.4% of all infants experienced at least
one infectious disease during follow-up (Table 2). Upper
respiratory tract infections, occurring in almost one out of
four infants, were the most common type of infectious dis-
ease. The incidence of infectious disease was signiﬁcantly
lower in the EF group than in the SF group (p = 0.005),
even after adjustment by logistic regression to take into
account the number of infectious diseases since birth
(p = 0.0004) and the personal (p = 0.0031) or family
(p = 0.0015) history of atopy. No difference was found
between groups when considering only the incidence of
infectious diseases during the ﬁrst month of follow-up (EF:
16.8%, SF: 18.3%, p = 0.58). Among subjects born after the
1st of April, there was signiﬁcantly less infections in EF
group (29,1%) than in SF group (40.1%) (p = 0.037).
Among subjects born before the 1st of April, there was a
tendency for less infections in EF group (32.7%) than in SF
group (41.4%) (p = 0.06). The mean number of infectious
diseases per month tended to be lower in the EF group than
in the SF group (p = 0.07), even after adjustment by covari-
ance analysis (p = 0.08). Regarding the types of infectious
diseases, only the incidence of gastrointestinal infections
differed between groups (p = 0.03); accordingly, fewer
infants in the EF group were prescribed anti-diarrhoea fol-
low-on formula (EF: 3.4%; SF: 7.4%; p = 0.02). There was a
tendency towards fewer antibiotic and antipyretic prescrip-
tions in the EF group compared to the SF group (Table S1).
Multivariate stepwise logistic regression revealed that the
following three factors were independently associated with
an increased risk of infectious disease in infants: frequent
infections in parents, the consumption of SF rather than EF
and the occurrence of infections before inclusion (Table 3).
The absence of breast feeding at inclusion tended to be asso-
ciated. The ﬁnal model included the 668 subjects with no
missing data in any of the four independent variables of the
model. The goodness-of-ﬁt of the model was quite good
(Hosmer–Lemeshow: Chi-square = 4.41, p = 0.73; Devi-
ance and Pearson criteria: Chi-square = 1).
DISCUSSION
In this clinical study, healthy 5-month-old infants fed EF
had a reduced incidence of infectious disease compared to
infants fed SF. To our knowledge, this is the ﬁrst longitudi-
nal study investigating the incidence of infectious diseases
in infants switching to follow-on formula EF.
The strengths of this study were the relatively large sam-
ple size, the detailed follow-up of infectious diseases and
nationwide recruitment. The study was initially designed to
be conducted solely during winter months (November–
April) to investigate the effects of synbiotics during the
season with the highest incidence of infectious diseases.
However, because of recruitment delays, it was not possible
to start the study before January, and the last patients were
included in June. This shift in the study period may have
resulted in underestimation of the clinical effects of syn-
biotics on infants. Intergroup comparisons are still relevant,
because similar percentages of infants were included before
April (i.e. during winter) in the two groups.
Table 2 Infectious disease incidence and type during follow-up in the intention-to-treat group (Mean [CI95])
n
EF group SF group All infants
419 347 771
Infectious disease
†(%) 31.0
* 40.6 35.4
Upper respiratory tract infections (%) 22.0 26.6 24.1
Otitis (%) 5.2 8.3 6.6
Acute diarrhoea (%) 3.5
* 6.8 5.0
Lower respiratory tract infectious disease (%) 5.2 4.3 5.8
Genital and urinary infectious disease (%) 0.2 0.2 0.2
Dermatologic infectious disease (%) 0.7 1.1 0.9
Ophthalmologic infectious disease (%) 1.6 1.4 1.5
Virus-related dermatologic infectious disease (%) 0.9 1.4 1.1
Monthly number of infectious diseases (n) 0.23 [0.18; 0.27] 0.25[0.21; 0.30] 0.24[0.21; 0.27]
*p < 0.05 versus SF (Student’s t-test or v
2⁄Fisher’s exact test).
†Percent of infants with at least one infectious disease during follow-up.
Table 3 Multivariate stepwise logistic regression analysis (n = 668) with the
occurrence of infectious disease as the independent factor.
Parameter Odds ratio 95%CI p
*
Frequent infection in parents 2.797 [1.462; 5.349] 0.0019
Standard follow-on formula as feeding
regimen
1.926 [1.380; 2.689] 0.0001
Infection in infants before inclusion 1.883 [1.338; 2.649] 0.0003
Absence of breast feeding at inclusion 1.384 [0.992; 1.930] 0.0558
*Wald test.
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been partly related with the delay in the study set-up. Even
though our target number of 418 subjects was not achieved
in the SF group, the inclusion time period was not extended
beyond June, because summer is a period of low risk for
infections. However, the number of subjects included in the
two groups was sufﬁcient to observe a signiﬁcant difference
in the main outcome criteria. It could have been also related
to an inclusion bias as paediatricians included more infants
in the EF group. They could have been inﬂuenced by the
familial and personal history of atopy or the greater number
of infections since birth, as paediatricians had probably pre-
viously heard about the potential positive effect on health of
prebiotics or probiotics. It could induce an overestimation
of synbiotic effects on prevention of infections in this spe-
ciﬁc population. However, the difference in prevalence of
infectious diseases between the two feeding groups persisted
after adjustment for the difference in the number of infec-
tions since birth and for difference in familial or personal
history of allergy.
In our study, around one-third of infants had at least
one infectious disease during the 3-month follow-up per-
iod. We only collected clinical data for infectious diseases,
but we compared information collected by paediatricians
with the information provided by parents. Only conﬁrmed
infectious diseases were used in our analyses. Our results
were in line with previous studies, indicating that the pres-
ent study probably did not overestimate the incidence of
infectious diseases. Recently, a large Australian cohort
study reported that half of all children were hospitalized at
least once by age two; infections (mainly respiratory and
gastrointestinal) were the most common reason for hospi-
talization, accounting for 34% of all admissions (13). In a
double-blind, randomized, placebo-controlled trial of
healthy children aged 1–6 years attending day care centres,
conducted over 7 months in Finland in 2001, the inci-
dence of respiratory tract infections (lower and upper) was
39% in children consuming formula supplemented with
Lactobacillus GG and 47% in children consuming stan-
dard formula (12). Another study reported a high inci-
dence of upper respiratory tract infections with frequent
complications, such as otitis and sinusitis: in children aged
6–35 months, 30% of upper respiratory tract infections
were complicated by acute otitis media (14). Respiratory
tract infections are associated with parental smoking; how-
ever, in the present study, only 15.4% of families reported
parental smoking, and there was no difference in parental
smoking in EF group and in the SF group. It is likely that
frequent exposure to infectious agents was responsible for
the high incidence of respiratory tract infections; this is
supported by epidemiological observations in France at the
time of the study.
The most convincing ﬁnding is the preventive effect
exerted against intestinal infections. This was supported by
the reduction in the incidence of diarrhoeal episodes in
infants receiving the symbiotic-enriched formula. It is note-
worthy that probiotics (15) and prebiotics (9) when given
separately have been found to give protection against acute
gastroenteritis. Because our study was not randomized, the
difference in infections between the two groups could have
been observed by chance. For example, the number of
infectious diseases since birth was signiﬁcantly higher in
the EF group than in the SF group. However, our results
persisted after adjustment for that difference between the
two groups.
EF was associated with a lower incidence of infectious
disease in our paediatric cohort compared to SF, both in
ITT analysis and also in PP analysis (PP: EF: 30.1%; SF:
39.0%; p = 0.001 after adjustment). This was in line with
previous studies, which reported that prebiotics and probi-
otics had beneﬁcial effects (7–9). In children over 2 years of
age, a synbiotic preparation was found to effectively treat
atopic dermatitis (16). Another study in children with short
bowel syndrome showed that synbiotic therapy improves
systemic immunonutritional status (11), and there was a
case report that a novel synbiotic therapy improved the
intestinal function of a paediatric patient with a laryngotra-
cheoesophageal cleft (17). In acutely ill children aged 1–
6 years, oral supplements containing synbiotics increased
energy intake and promoted weight gain (18). Regarding
intergroup comparisons of EF versus SF, this open study
was intended to be a preliminary analysis: further random-
ized, double-blind, controlled trials are needed to conﬁrm
the clinical beneﬁts of EF.
The mechanisms of action of synbiotics are probably simi-
lar to those of prebiotics and probiotics, with possible
synergistic effects as demonstrated in animals (19). The
mechanisms include resistance to colonization by patho-
gens through production of inhibitory substances, blockage
of adhesion sites, competition for nutrients, degradation of
toxin receptors and stimulation of immunity (20).
The preventive effect on infections was not the only clini-
cal effect we observed. Infants fed the EF gained signiﬁ-
cantly more weight than those fed SF, but that difference is
not clinically relevant over such a short period. It is always
possible that this result was non-speciﬁc; however, weight
gain was observed in parallel with increases in length. Such
a difference could be more important over a longer period.
This positive effect on growth could be related to the
reduced incidence of infectious diseases during this period
or could alternatively be attributable to the effect of pro-
biotics or prebiotics on digestive microﬂora (15). A positive
relationship between digestive microﬂora and growth has
been suggested in animals (21,22), preterm infants (23) and
older infants treated with antibiotics (18). Further investiga-
tors should be encouraged to evaluate speciﬁcally the
growth in infants fed with formulas that are able to have an
impact on intestinal microﬂora.
In conclusion, this clinical study indicates that infectious
diseases affect more than one-third of healthy 5-month-old
infants in the 3 months following a switch to follow-on for-
mula and suggests an association between the administra-
tion of a synbiotic-enriched follow-on formula and clinical
effects in healthy infants. Randomized clinical trials are
needed to understand the mechanisms and clinical effects
of synbiotics, especially in infants less than 1 year of age.
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probiotics must also be established.
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